INHIBRX BIOSCIENCES, INC. Financing Cash Flow
INHIBRX BIOSCIENCES, INC. (INBX) reported Financing Cash Flow of $77.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.60M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $75.46M, a 24.42% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.25M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $352.00K.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2025 was $101.45M, a 41.53% increase from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2024 was $71.68M, a 64.51% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2023 was $201.96M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $77.07M 10-Q · filed 2026-08-13 | $78.32M derived: sum of 3 quarters · filed 2026-08-13 | $78.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $75.46M 10-Q · filed 2026-05-14 | $76.72M derived: sum of 2 quarters · filed 2026-05-14 | $77.07M derived: sum of 3 quarters · filed 2026-05-14 | $77.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.61M derived: sum of 2 quarters · filed 2026-03-19 | $1.61M derived: sum of 3 quarters · filed 2026-08-13 | $101.45M 10-K · filed 2026-03-19 |
| 2025-09-30 | $352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $352.00K derived: sum of 2 quarters · filed 2026-08-13 | $100.19M 10-Q · filed 2025-11-14 | $100.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $99.84M 10-Q · filed 2026-08-13 | $99.84M derived: sum of 3 quarters · filed 2026-08-13 | $99.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $99.84M 10-Q · filed 2026-05-14 | $99.84M derived: sum of 2 quarters · filed 2026-05-14 | $99.84M derived: sum of 3 quarters · filed 2026-05-14 | $132.79M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $32.95M derived: sum of 3 quarters · filed 2026-03-19 | $71.68M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $32.95M derived: sum of 2 quarters · filed 2025-11-14 | $71.68M 10-Q · filed 2025-11-14 | $72.54M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $32.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $71.68M 10-Q · filed 2025-08-13 | $72.54M derived: sum of 3 quarters · filed 2025-08-13 | $272.43M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $38.73M 10-Q · filed 2025-05-14 | $39.59M derived: sum of 2 quarters · filed 2025-05-14 | $239.48M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $860.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $200.75M derived: sum of 2 quarters · filed 2025-03-17 | $201.96M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $199.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $201.10M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $1.21M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |